Valuation : Nuvectra Corporation

Market Cap 16.99L 14.62L 13.76L 12.57L 23.51L 16Cr 23.57L 1.63Cr 63.08L 8.23Cr 63.8L 62.41L 27Cr P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -5.35Cr -4.6Cr -4.33Cr -3.95Cr -7.4Cr -504.74Cr -7.42Cr -51Cr -20Cr -258.96Cr -20Cr -20Cr -834.26Cr EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 3L
-0.42%-3.68%-18.43%+5.33% 19TCr
+1.15%+3.22%+1.42%+14.66% 12TCr
-1.86%+2.77%+13.07%+89.16% 6.32TCr
-1.31%-1.09%+22.44%+46.84% 5.17TCr
-1.54%-2.52%-3.41%-33.66% 5.03TCr
-2.02%-3.22%+8.84%-13.73% 3.32TCr
0.00%+3.71% - - 3.21TCr
-0.81%+0.74%+37.34%-16.61% 2.39TCr
-1.44%-4.21%-7.37%+11.97% 2.3TCr
Average -0.82%+1.60%+6.74%+12.99% 5.85TCr
Weighted average by Cap. -0.55%+0.02%-0.82%+15.45%

Financials

2017 2018
Net sales 3.18Cr 2.74Cr 2.58Cr 2.35Cr 4.4Cr 300.58Cr 4.42Cr 30Cr 12Cr 154.22Cr 12Cr 12Cr 496.82Cr 4.88Cr 4.2Cr 3.95Cr 3.61Cr 6.76Cr 461.04Cr 6.77Cr 47Cr 18Cr 236.55Cr 18Cr 18Cr 762.04Cr
Net income -4.46Cr -3.84Cr -3.61Cr -3.3Cr -6.17Cr -421.09Cr -6.19Cr -43Cr -17Cr -216.05Cr -17Cr -16Cr -696.01Cr -4.81Cr -4.14Cr -3.9Cr -3.56Cr -6.66Cr -454.43Cr -6.68Cr -46Cr -18Cr -233.16Cr -18Cr -18Cr -751.12Cr
Net Debt -14.9L -12.82L -12.06L -11.02L -20.61L -14Cr -20.67L -1.43Cr -55.31L -7.22Cr -55.95L -54.73L -23Cr -5.52Cr -4.75Cr -4.47Cr -4.08Cr -7.63Cr -520.78Cr -7.65Cr -53Cr -20Cr -267.2Cr -21Cr -20Cr -860.78Cr
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock